Recombinant Human Antibody (EDE2 A11) is capable of binding to DENV E proteins, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-DENV E proteins mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-DENV E proteins mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.
Figure 1 Neutralization curves using three antibodies each from the three subsets FLE, EDE1 and EDE2.
Results represent the mean ± s.e.m. of four independent experiments performed in triplicate for PF13 and in duplicate for HD78788 strains. The two ZIKV strains are in bright colours, blue and red, respectively. The neutralization data for the four DENV serotypes are given here for comparison. Note that the DENV-4 strain used was a natural isolate lacking the N153 glycosylation site (N−).
Figure 2 ZIKV sE reactivity with human recombinant full-length antibodies FLE P6B10, EDE1 C8 and EDE2 A11. Left, binding properties were monitored by biolayer interferometry (BLI) on Octet-Red (ForteBio).
The normalized response values expressed as fraction of binding site occupancy are plotted against concentrations of ZIKV sE dimer shown at logarithmic scale. Lines denote global curve fits used for Kd evaluation.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.